Balyasny Asset Management L.P. Invests $4.95 Million in Upstream Bio, Inc. (NASDAQ:UPB)

Balyasny Asset Management L.P. acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 301,152 shares of the company’s stock, valued at approximately $4,951,000. Balyasny Asset Management L.P. owned 0.56% of Upstream Bio as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in shares of Upstream Bio in the fourth quarter worth about $25,000. US Bancorp DE purchased a new position in shares of Upstream Bio during the fourth quarter worth approximately $27,000. Legal & General Group Plc bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio in the fourth quarter worth approximately $47,000.

Upstream Bio Stock Down 1.2 %

Shares of NASDAQ UPB opened at $8.73 on Friday. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46. The business has a fifty day simple moving average of $8.03 and a two-hundred day simple moving average of $13.50.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, sell-side analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.